Product Description
Bezafibrate is an agonist of peroxisome proliferator-activated receptor alpha (PPARalpha) with antilipidemic activity. Bezafibrate decreases triglyceride levels, increases high density lipoprotein (HDL) cholesterol levels, and decreases total and low density lipoprotein (LDL) cholesterol levels.
Mechanisms of Action: PPAR-a Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Belgium | Brazil | Canada | Chile | China | Colombia | Cyprus | Ecuador | Finland | France | Germany | Hong Kong | Hungary | India | Indonesia | Israel | Italy | Korea | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Pakistan | Peru | Portugal | Romania | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Intercept
Company Location: NEW YORK NY 10001
Company CEO: Jerome Durso
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Croatia, Czech Republic, Estonia, France, Germany, Hungary, Netherlands, Norway, Spain, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Biliary Cirrhosis|Cholangitis|Liver Cirrhosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 747-213 | P2 |
Not yet recruiting |
Biliary Cirrhosis|Cholangitis |
2025-10-31 |
|
| - | P2 |
Active, not recruiting |
Cholangitis|Biliary Cirrhosis |
2025-10-20 |
|
| NCT05239468 | P2 |
Active, not recruiting |
Cholangitis|Biliary Cirrhosis|Liver Cirrhosis |
2024-11-01 |